Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Abivax SA Sponsored ADR, and Palvella Therapeutics. According to TipRanks, Slutsky has an average return of 43.2% and a 51.21% success rate on recommended stocks.
In a report released on May 14, Roth MKM also assigned a Buy rating to the stock with a $19.00 price target.
Based on Immunic’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $32.59 million. In comparison, last year the company had a GAAP net loss of $25.47 million
